TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Blinded Cross-Over Clinical Trial Investigate the Interactions Between Influenza Vaccination and Oral Anticoagulant Therapy
Brief Summary: The purpose of this study is to evaluate INR and INR related index and Warfarin weekly dosage variations after Influenza Vaccination


Options:
A: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A
B: Arm Label: Influenza A (H5N1) 18-64Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo 18-64Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) >64Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo >64Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) 18-60Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo 18-60Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) >60Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo >60Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Assigned to Arm(s): Influenza A (H5N1) 18-60Y Group, Influenza A (H5N1) 18-64Y Group, Influenza A (H5N1) >60Y Group, Influenza A (H5N1) >64Y Group, Influenza A (H5N1) Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo 18-60Y Group, Placebo 18-64Y Group, Placebo >60Y Group, Placebo >64Y Group, Placebo Group
C: Arm Label: FluNG Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Bio's influenza vaccine GSK2186877A | Arm Label: Fluarix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fluarix TM | Intervention Type: BIOLOGICAL; Name: GSK Bio's influenza vaccine GSK2186877A; Assigned to Arm(s): FluNG Group | Intervention Type: BIOLOGICAL; Name: Fluarix TM; Assigned to Arm(s): Fluarix Group
D: Intervention Type: DRUG; Name: Influenza vaccination; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction
Brief Summary: To assess the efficacy and safety of Tenecteplase versus Placebo in normotensive patients with sub-massive Pulmonary Embolism and Right Ventricular Dysfunction (RVD) all receiving unfractionated heparin (UFH)


Options:
A: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline + Enoxaparin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenecteplase + Enoxaparin | Intervention Type: DRUG; Name: Tenecteplase + Enoxaparin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0.9% Saline + Enoxaparin; Assigned to Arm(s): 2
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2
C: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
D: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction
Brief Summary: To assess the efficacy and safety of Tenecteplase versus Placebo in normotensive patients with sub-massive Pulmonary Embolism and Right Ventricular Dysfunction (RVD) all receiving unfractionated heparin (UFH)


Options:
A: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
B: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin
C: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction
Brief Summary: To assess the efficacy and safety of Tenecteplase versus Placebo in normotensive patients with sub-massive Pulmonary Embolism and Right Ventricular Dysfunction (RVD) all receiving unfractionated heparin (UFH)


Options:
A: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: Patients undergoing Pulmonary Embolectomy; Type: N/A; Interventions: Procedure: Catheter directed debulking of Pulmonary Embolus | Intervention Type: PROCEDURE; Name: Catheter directed debulking of Pulmonary Embolus; Assigned to Arm(s): Patients undergoing Pulmonary Embolectomy
D: Arm Label: pulmonary embolism; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.
Brief Summary: To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism


Options:
A: Arm Label: Medical; Type: N/A; Interventions: Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux | Arm Label: Intensive; Type: N/A; Interventions: Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux | Intervention Type: DRUG; Name: thromboprophylaxis with low-molecular-weight heparin or fondaparinux; Assigned to Arm(s): Intensive, Medical
B: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A
C: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care thromboprophylaxis | Arm Label: Interventional; Type: OTHER; Interventions: Drug: Intermediate dose thromboprophylaxis | Intervention Type: DRUG; Name: Intermediate dose thromboprophylaxis; Assigned to Arm(s): Interventional | Intervention Type: DRUG; Name: Standard of Care thromboprophylaxis; Assigned to Arm(s): Standard of Care
D: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.
Brief Summary: To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism


Options:
A: Arm Label: Intensive anticoagulation strategy; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH) | Arm Label: Moderate anticoagulation strategy; Type: OTHER; Interventions: Drug: Low dose Low molecular weight heparin or Placebo | Intervention Type: DRUG; Name: Anticoagulation Agents (Edoxaban and/or high dose LMWH); Assigned to Arm(s): Intensive anticoagulation strategy | Intervention Type: DRUG; Name: Low dose Low molecular weight heparin or Placebo; Assigned to Arm(s): Moderate anticoagulation strategy
B: Arm Label: Test Group; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml; Assigned to Arm(s): Test Group
C: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux
D: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.
Brief Summary: To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A
D: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.
Brief Summary: To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism


Options:
A: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group
B: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A
C: Arm Label: MED-Cohort; Type: N/A; Interventions: Drug: Low Molecular Weight Heparin | Arm Label: ICU-Cohort; Type: N/A; Interventions: Drug: Low Molecular Weight Heparin | Intervention Type: DRUG; Name: Low Molecular Weight Heparin; Assigned to Arm(s): ICU-Cohort, MED-Cohort
D: Arm Label: Enoxaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Current standard of care (no enoxaparin); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Adherence in Type 2 Diabetics
Brief Summary: This randomized study will test a behavioral intervention, based on social cognitive theory (SCT), to improve regimen adherence in three different groups of people with type 2 diabetes; (1) those with well controlled blood glucoses and no concurrent chronic renal insufficiency, (2) those with less well-controlled glucoses and no chronic renal insufficiency, and (3) those with chronic renal insufficiency regardless of glucose control. The primary aims of this study are to: (1)determine whether the intervention improves behavioral adherence to the diabetes self-management regimen including dietary adherence, physical activity, and capillary glucose self-monitoring; (2)determine whether the intervention improves clinical outcomes; (3) explore the extent to which self-efficacy is a mediator of adherence,(4) explore the extent to which the effectiveness of the intervention varies with respect to glycemic control and nephrovascular complications at baseline, and (5)explore the impact of a variety of covariates on the effectiveness of the intervention.

Hypothesis #1 is that intervention group participants will perform better than attention control group participants on various measures of adherence to the diabetes management regimen. Primary adherence variables will be dietary intake, and physical activity. Hypothesis #2 is that intervention group participants will have lower HbA1c levels than attention control group participants.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Internet Intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Internet Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Routine general practice care; Type: NO_INTERVENTION; Interventions: Behavioral: Structured personal care | Intervention Type: BEHAVIORAL; Name: Structured personal care; Assigned to Arm(s): Routine general practice care
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): B
D: Arm Label: Low intensity; Type: ACTIVE_COMPARATOR; Interventions: Other: Low intensity | Arm Label: Moderate intensity; Type: EXPERIMENTAL; Interventions: Other: Moderate intensity | Arm Label: High intensity; Type: EXPERIMENTAL; Interventions: Other: High intensity | Intervention Type: OTHER; Name: Low intensity; Assigned to Arm(s): Low intensity | Intervention Type: OTHER; Name: Moderate intensity; Assigned to Arm(s): Moderate intensity | Intervention Type: OTHER; Name: High intensity; Assigned to Arm(s): High intensity

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Adherence in Type 2 Diabetics
Brief Summary: This randomized study will test a behavioral intervention, based on social cognitive theory (SCT), to improve regimen adherence in three different groups of people with type 2 diabetes; (1) those with well controlled blood glucoses and no concurrent chronic renal insufficiency, (2) those with less well-controlled glucoses and no chronic renal insufficiency, and (3) those with chronic renal insufficiency regardless of glucose control. The primary aims of this study are to: (1)determine whether the intervention improves behavioral adherence to the diabetes self-management regimen including dietary adherence, physical activity, and capillary glucose self-monitoring; (2)determine whether the intervention improves clinical outcomes; (3) explore the extent to which self-efficacy is a mediator of adherence,(4) explore the extent to which the effectiveness of the intervention varies with respect to glycemic control and nephrovascular complications at baseline, and (5)explore the impact of a variety of covariates on the effectiveness of the intervention.

Hypothesis #1 is that intervention group participants will perform better than attention control group participants on various measures of adherence to the diabetes management regimen. Primary adherence variables will be dietary intake, and physical activity. Hypothesis #2 is that intervention group participants will have lower HbA1c levels than attention control group participants.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth | Intervention Type: BEHAVIORAL; Name: mHealth; Assigned to Arm(s): mHealth
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): B
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard hemodialysis dietary instruction | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling plus PDA-based self-monitoring of diet | Intervention Type: BEHAVIORAL; Name: Standard hemodialysis dietary instruction; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling plus PDA-based self-monitoring of diet; Assigned to Arm(s): B
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: iChoose Kidney Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: iChoose Kidney Decision Aid | Intervention Type: BEHAVIORAL; Name: iChoose Kidney Decision Aid; Assigned to Arm(s): iChoose Kidney Decision Aid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults
Brief Summary: The purpose of this study is to determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.


Options:
A: Arm Label: Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: ALVAC-HIV vCP1521 + AIDSVAX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: ALVAC Placebo + AIDSVAX Placebo | Intervention Type: BIOLOGICAL; Name: ALVAC-HIV vCP1521 + AIDSVAX; Assigned to Arm(s): Vaccine | Intervention Type: OTHER; Name: ALVAC Placebo + AIDSVAX Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: PROCEDURE; Name: Adult male circumcision; Assigned to Arm(s): N/A
C: Arm Label: Circumcised immediately; Type: ACTIVE_COMPARATOR; Interventions: Procedure: male circumcision | Arm Label: Delayed Circumcision; Type: PLACEBO_COMPARATOR; Interventions: Procedure: male circumcision | Intervention Type: PROCEDURE; Name: male circumcision; Assigned to Arm(s): Circumcised immediately, Delayed Circumcision
D: Intervention Type: PROCEDURE; Name: Male Circumcision; Assigned to Arm(s): N/A

Answer: A